Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Astegolimab in COPD (Open-Label Extension GB43374/ALNASA)
jRCT2031240596Phase 3Recruiting
- Sponsor
- Roche
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of astegolimab in chronic obstructive pulmonary disease (COPD), sponsored by Roche. Primary endpoint: Incidence and severity of adverse events. Started Mar 2025; status: recruiting.
02
Drugs
astegolimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2031240596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240596.